These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17425663)

  • 1. ABO blood group, other risk factors and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE).
    Ohira T; Cushman M; Tsai MY; Zhang Y; Heckbert SR; Zakai NA; Rosamond WD; Folsom AR
    J Thromb Haemost; 2007 Jul; 5(7):1455-61. PubMed ID: 17425663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.
    Folsom AR; Cushman M; Tsai MY; Aleksic N; Heckbert SR; Boland LL; Tsai AW; Yanez ND; Rosamond WD
    Blood; 2002 Apr; 99(8):2720-5. PubMed ID: 11929758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total tissue factor pathway inhibitor and venous thrombosis. The Longitudinal Investigation of Thromboembolism Etiology.
    Zakai NA; Lutsey PL; Folsom AR; Heckbert SR; Cushman M
    Thromb Haemost; 2010 Aug; 104(2):207-12. PubMed ID: 20431849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study.
    Larsen TB; Johnsen SP; Gislum M; Møller CA; Larsen H; Sørensen HT
    J Thromb Haemost; 2005 Feb; 3(2):300-4. PubMed ID: 15670036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peak thrombin generation and subsequent venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE) study.
    Lutsey PL; Folsom AR; Heckbert SR; Cushman M
    J Thromb Haemost; 2009 Oct; 7(10):1639-48. PubMed ID: 19656279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.
    Tirado I; Mateo J; Soria JM; Oliver A; Martínez-Sánchez E; Vallvé C; Borrell M; Urrutia T; Fontcuberta J
    Thromb Haemost; 2005 Mar; 93(3):468-74. PubMed ID: 15735796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies.
    Nemeth B; van Adrichem RA; van Hylckama Vlieg A; Bucciarelli P; Martinelli I; Baglin T; Rosendaal FR; le Cessie S; Cannegieter SC
    PLoS Med; 2015 Nov; 12(11):e1001899; discussion e1001899. PubMed ID: 26554832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type.
    Sode BF; Allin KH; Dahl M; Gyntelberg F; Nordestgaard BG
    CMAJ; 2013 Mar; 185(5):E229-37. PubMed ID: 23382263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism.
    Shrivastava S; Ridker PM; Glynn RJ; Goldhaber SZ; Moll S; Bounameaux H; Bauer KA; Kessler CM; Cushman M
    J Thromb Haemost; 2006 Jun; 4(6):1208-14. PubMed ID: 16706961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-density lipoprotein receptor-related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism.
    Vormittag R; Bencur P; Ay C; Tengler T; Vukovich T; Quehenberger P; Mannhalter C; Pabinger I
    J Thromb Haemost; 2007 Mar; 5(3):497-502. PubMed ID: 17155964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High risk for venous thromboembolism in diabetics with hyperosmolar state: comparison with other acute medical illnesses.
    Keenan CR; Murin S; White RH
    J Thromb Haemost; 2007 Jun; 5(6):1185-90. PubMed ID: 17403099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective study of fibrinolytic markers and venous thromboembolism.
    Folsom AR; Cushman M; Heckbert SR; Rosamond WD; Aleksic N
    J Clin Epidemiol; 2003 Jun; 56(6):598-603. PubMed ID: 12873656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors.
    Ribeiro DD; Lijfering WM; Rosendaal FR; Cannegieter SC
    J Thromb Haemost; 2016 Aug; 14(8):1572-8. PubMed ID: 27214710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism--a manifestation of the metabolic syndrome.
    Ay C; Tengler T; Vormittag R; Simanek R; Dorda W; Vukovich T; Pabinger I
    Haematologica; 2007 Mar; 92(3):374-80. PubMed ID: 17339187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
    Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
    Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism.
    Vormittag R; Vukovich T; Schönauer V; Lehr S; Minar E; Bialonczyk C; Hirschl M; Pabinger I
    Thromb Haemost; 2005 Mar; 93(3):488-93. PubMed ID: 15735799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism.
    Kraaijenhagen RA; in't Anker PS; Koopman MM; Reitsma PH; Prins MH; van den Ende A; Büller HR
    Thromb Haemost; 2000 Jan; 83(1):5-9. PubMed ID: 10669145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
    Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
    Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE).
    Tsai AW; Cushman M; Rosamond WD; Heckbert SR; Tracy RP; Aleksic N; Folsom AR
    Am J Med; 2002 Dec; 113(8):636-42. PubMed ID: 12505113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.